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A B S T R A C T
Paralytic Shellﬁsh Poisoning (PSP) toxins are some of the most toxic substances known to man and con-
sumption of shellﬁsh containing these naturally-occurring neurotoxins can lead to a range of different
symptoms including death in extreme cases. It is imperative therefore, to implement robust shellﬁshmoni-
toring programs tominimise the possibility of contaminated product reaching themarketplace. To improve
the quality assurance of these programs, QUASIMEME, the proﬁciency test provider added to its scope PSP
toxins in shellﬁsh. Since 2009, six proﬁciency testing exercises have been delivered by QUASIMEME with
a total of thirty-four different laboratories submitting data using a range of different methods. These include
animal and antibody based assays, together with High Performance Liquid Chromatography (HPLC) tech-
niques using post and pre-column oxidation and more recently LC-MS/MS methodologies.
Data from these exercises is presented and laboratory performance is assessed to determine any changes
in overall performance over the six rounds, together with any potential method-related performance issues.
The data showed the improvement of laboratories over the six exercises with between laboratory CV%
values decreasing from an average of 39% in the ﬁrst year to 22% in 2014 and the average percentage of
participants receiving satisfactory z-scores increasing from 50% in 2009 to over 66% in 2014.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Paralytic shellﬁsh poisoning (PSP) is caused by a group of over
30 structurally similar analogues based on a tetrahydropurine skel-
eton and produced, mainly, by some marine dinoﬂagellates (Fig. 1)
[1,2]. These potent neurotoxins can accumulate in the food chain
through the ﬁlter-feeding of toxin-producing algae by bivalvemollusc
shellﬁsh. Subsequent consumption of contaminated shellﬁsh can
result in human intoxication, with symptoms including numbness
in the extremities, tingling in the face, nausea, vomiting, diar-
rhoea and in severe cases, death by asphyxiation [3].
PSP toxin proﬁles in shellﬁsh differ substantially worldwide and
variations occur for a number of reasons. The toxin proﬁle differs
between algal species, between strains of the same species, between
species in different geographical locations or even between iso-
lates from the same location [4,5]. Differences also exist in the
metabolic transformation of some PSP toxins into others from various
shellﬁsh species [6]. This can lead to issues for PSP proﬁciency test
(PT) providers in supplying materials with a wide range of pro-
ﬁles to cater to participants from different geographical locations.
Numerous intoxications and incidences have been reported from
around the world [7–12] and with global aquaculture production
reaching record levels of 90.4 million tonnes in 2012 (US$144.4
billion) [13], it is vital, for human protection and as a statutory re-
quirement in many countries, to implement robust shellﬁsh
monitoring programs [14,15].
Essential to any effective monitoring program is the proper ap-
plication of a qualitymanagement system, incorporating both quality
assurance and quality control [16]. PT plays a vital role in the im-
plementation of these programs, and participation in these schemes
is a requirement both legislatively in the EU [17,18] as well as by
most national accreditation bodies.
QUASIMEME (Quality Assurance of Information in Marine En-
vironmental Monitoring) was founded in 1992 and was initially
funded by the European Union (EU). The aim was to establish a
comprehensive network of laboratories producing demonstrably re-
liable chemical information while providing a holistic approach to
quality assurance. The determination of PSP toxins was added to
the QUASIMEME scope in 2009 as a development exercise, with one
round being organised per year.
The aim of this review is to disseminate the data generated over
the previous six years of PSP PT delivered by QUASIMEME and to
highlight issues related to the analysis of this toxin group by the
various methods used by participants. The review seeks to high-
light the advantages of PT participation and shows the development
of the exercises through laboratory performance.
1.1. Toxicity equivalency factor (TEF)
The PSP analogues differ substantially in their toxicity and their
TEFs have been derived from MBA data. Fig. 1 lists the TEFs re-
ported by Oshima et al. in 1995 [19] alongside values compiled by
the Scientiﬁc Panel on Contaminants in the Food Chain (CONTAM)
of the European Food Safety Authority (EFSA) in 2009 [20]. The two
sets of ﬁgures are similar with the exception of dcSTX where the
TEF was increased to 1.0 from 0.5 by the CONTAM panel. This change
would signiﬁcantly affect reported total toxicities of samples with
dcSTX as the predominant toxin present which is the case in some
of the samples supplied by QUASIMEME.
1.2. Methods of analysis
There are few internationally recognised methods available for
determining PSP toxins. Table 1 lists the numbers of participants
Fig. 1. Chemical structure of the PSP toxins together with toxicity equivalence factors (TEFs) reported by Oshima and those recommended by the European Food Safety
Authority (EFSA).
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over the last six years and the methods employed are brieﬂy de-
scribed below:
1. Mouse bioassay (MBA): The MBA was ﬁrst applied in the deter-
mination of PSP toxicity by Sommer and Meyer in 1937
[21]. Subsequently the procedure underwent standardisation,
culminating in association of analytical communities (AOAC) of-
ﬁcial method (OMA) 959.08 [22]. This is the reference method
speciﬁed in EU legislation [23] and involves the extraction of the
shellﬁsh homogenate tissue in dilute hydrochloric acid followed
by intraperitoneal injection of ﬁltered extracts into replicatemice.
The time taken from injection tomouse death is recorded and the
toxicity determined from a conversion table developed by Sommer
and Meyer [21]. Reported drawbacks of the method include un-
derestimations of total toxicity caused by high salt concentrations
or the presence of some metals in samples [3,24]. The presence
of other metals, such as zinc, particularly evidenced in oyster
tissues has been reported to increase the threat of false posi-
tives [25]. The method is also controversial in its use of large
numbers of mice and in stipulating death as an endpoint. A further
drawback of the MBA is that it only provides a total toxicity value
and no information about the speciﬁc toxin proﬁle of a sample.
However, the method has been used globally for many years and
has provided an excellent preventative method for the signiﬁ-
cant reduction of PSP intoxications worldwide.
2. Liquid Chromatography-Fluorescence Detection (LC-FLD): PSP
toxins do not exhibit natural ultraviolet absorption or ﬂuores-
cence andmust therefore be oxidised into ﬂuorescent derivatives
before detection by FLD. This oxidation process can be carried
out either before or after separation by LC and has given rise to
two distinct LC methods.
a. Pre-column Oxidation (preCOX): two preCOX methods were
used by participants. The ﬁrst, also called the “Lawrence
method” is the only named alternative to the MBA usable for
oﬃcial control testing in the EU and was written into EU leg-
islation in 2006 [23]. The second closely-relatedmethod, used
by one participant in 2014 is that described by the European
Committee for Standardisation (CEN) and recently published
as European standard DIN EN 14526 [26]. Bothmethods involve
the oxidation of toxins into iminopurine derivatives before sep-
aration and determination by LC-FLD. The method cited in
legislationwas originally developed by Lawrence andMeynard
[27] and underwent international validation in 2004 before
being approved as an AOAC oﬃcial method in 2005 [28]. The
method is based on a two-step boiling acetic acid extraction
followed by cleanup steps using solid phase extraction (SPE).
Extracts are then oxidised using periodic acid or hydrogen per-
oxide depending on the toxin proﬁle present. The main
drawbacks of the method relate to the complex chromato-
graphic output aswell as the lack of separation of epimeric pairs
(gonyautoxins 1&4 (GTX1 & GTX4), GTX2 & GTX3, C1 & C2,
decarbamoylgonyautoxin 2&3 (dcGTX2 & dcGTX3) and C3 &
C4) characteristic of this toxin group. Users of this method cal-
culate summed toxin concentrations for each epimeric pair.
Sample toxicities are estimated from the sum of toxin con-
centrations, which leads to a slight overestimation as themore
toxic analogue for each epimer pair is used to calculate total
toxicity. This is in spite of the fact that the epimer ratio in bivalve
tissues typically reaches an equilibrium of 3:1 predominated
by the less toxic α-epimers (GTX1, 2) compared to the more
toxic β-epimers (GTX3, 4) [29]. Pre-column derivatization can
produce one to three oxidation product peaks per toxin, leading
to diﬃculties in determining toxin proﬁles and accurate
quantitation. This is particularly pertinent for samples often
used in PT schemes where two or more different toxin pro-
ﬁles are mixed to prepare the RMs or the analysis of toxin
proﬁles not routinely encountered at the participants labora-
tory. Another drawback of using this method and all chemical
basedmethods of analysis is the lack of certiﬁed reference stan-
dards for all the PSP toxins, most notably GTX6, C3, C4, dcGTX1
and dcGTX4. Example chromatograms, generated from preCOX
LC-FLD analysis are illustrated in Fig. 2a–b which highlight the
complex chromatographic output from this method
and some of the potential issues in accurate identiﬁcation. Al-
though complex, themethod has been reﬁned and standardised
since acceptance as a ﬁrst action AOACmethod, and in recent
years has been implemented into routine oﬃcial control testing
of shellﬁsh in a number of countries including Ireland, UK, Por-
tugal and New Zealand.
b. Post-column oxidation (PCOX): methods based on post-
columnderivatizationwere ﬁrst utilised for shellﬁshmonitoring
by Sullivan andWekell in 1984 [30]. Further developmentswere
described by Oshima et al. in 1989where separation of the full
suite of known PSP toxins was achieved using three separate
chromatographic conditions [31]. Amethodmodiﬁed from that
of Oshima [19] and subsequently Thomas et al. [32] was pub-
lished by Rourke et al. in the journal of the AOAC in 2008 [33].
This method underwent international validation in 2010 and
was accepted as AOAC OMA 2011.02 [34]. The extraction tech-
nique is based on that of the MBA, with the use of boiling
hydrochloric acid. Partial hydrolysis of certain PSP toxins into
more toxic analogues occurs with the PCOX/MBA extraction
method which, some argue, mimics the process of digestion
in the stomach thereby more accurately reﬂecting sample po-
tential toxicity [26]. The milder conditions of the preCOX
extraction method do not cause hydrolysis of the toxins, with
toxin proﬁle consequently remaining unaffected. A distinct ad-
vantage the PCOXmethod has over the preCOXmethod is the
formers ability to separate the PSP epimers contained in this
group [35]. One disadvantage with the PCOXmethods is their
inability to separate certain PSP toxins (dcNEO/NEO and GTX6/
GTX4) unless a very long runtime is used [33]. OMA 2011.02
also requires two chromatographic runs in order to separate
the full suite of PSP toxins. The method has recently been
adopted into US legislation and has been implemented into of-
ﬁcial control monitoring programswithin Canada, Norway and
some US states. Chromatograms obtained from PCOX LC-FLD
analysis of a material used in these exercises are provided in
Fig. 2c–d, which clearly shows the separation of the epimer
pairs contained in the sample.
3. Assays: The immunoassay technique used by QUASIMEME par-
ticipants for PSP testing is that of a competitive enzyme-linked
immunosorbent assay (ELISA). A number of kits are commercial-
ly available, although the one used for reporting QUASIMEME
samples is available under the name Ridascreen™ (R-Biopharm,
Darmstadt, Germany) and is based on the competition between
free PSP toxins and PSP toxin conjugates for PSP antibody binding
sites. The high number of saxitoxin (STX) congeners has posed
problems for developers of these methods, with, for example,
neosaxitoxin (NEO) and GTX1,4 exhibiting poor cross reactivity
Table 1
Total number of participants in each round including breakdown of methods used
Year Round Methods Used Total Number
of Participants
preCOX PCOX MBA ELISA LC-MS/MS
2009 57 8 2 4 – – 14
2010 61 9 5 2 – – 16
2011 65 8 5 4 2* – 19
2012 69 9 5 2 – – 16
2013 72 13 6 2 – 1 22
2014 2014-1 13 5 2 – 3 23
* Ridascreen ELISA used by participants.
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with the Ridascreen assay [36]. Other immunological test kits avail-
able commercially suffer the same cross reactivity issues
described above apart from one test kit supplied by Neogen, where
the cross reactivity of NEO was improved [37]. A hydrolysis step
has also been implemented by one kit supplier, Scotia Rapid Testing
Ltd., which converts GTX1,4 to NEO in order to circumvent some
of the GTX1,4 cross reactivity issues [38].
A receptor binding assay (RBA) was ﬁrst developed in the early
90’s by Vieytes et al. [39] and after extensive method reﬁne-
ment and further development was accepted as an oﬃcial AOAC
method of analysis in 2011 (OMA AOAC 2011.27) [40]. Al-
though the method has performed well in comparison with the
MBA and HPLC [41], its use in routine monitoring programmes
has been limited in part by the reliable availability of tritiated
saxitoxin and from the use and handling of radioisotopes used
in the method. The RBA has not been used for the analysis of
any Quasimeme samples to date.
4. Liquid Chromatography – Tandem Mass Spectrometry (LC-MS/
MS): The use of mass spectrometry as a detection system for
determining PSP toxins is desirable, based on the high sensitiv-
ity and selectivity this technique potentially gives the user. Early
LC-MS/MS methods required the use of ion-pairing reagents in
the mobile phase in order to ensure adequate retention of the
charged PSP species [42,43]. This, along with the aqueous mobile
phase these methods employed, leads to poor ionization and
signal suppression. Hydrophilic interaction liquid chromatog-
raphy (HILIC), which does not require the use of ion pairing
reagents, was ﬁrst utilised for PSP determination by Dell’Aversano
et al. in 2005 [44]. The technique is ideally suited to the sepa-
ration of polar compounds and for electrospray ionisation (ESI)
MS detection owing to the high organic content of mobile phases
used [44]. Despite these advantages the technique still suffers
from signiﬁcant matrix effects issues caused by salts and co-
extractives present. These issues coupled with the high detection
limits reported have limited this methods use in monitoring pro-
grammes, despite improved sensitivity compared to previously
developed LC-MS/MSmethods [44]. Recent developments in the
ﬁeld have focused on sample pre-treatment in order to over-
come the issues highlighted above. Boundy et al. reported on an
effective desalting pre-treatment cleanup step using inexpen-
sive graphitised carbon SPE cartridges prior to HILIC separation
andMS detection [45]. The procedure reducedmatrix effects sub-
stantially and the method was subjected to an extensive single-
laboratory validation study on various shellﬁsh species as reported
by Turner et al. [46]. Method sensitivity was signiﬁcantly in-
creased and detection limits were found to be similar or below
those reported for both preCOX and PCOX LC-FLD methods. This
represents a major breakthrough in overcoming the technical
issues that have traditionally affected LC-MS/MS determina-
tion of PSP toxins in complex matrices. The use of LC-MS/MS
methods for PSP testing by QUASIMEME participants has been
limited to date with results submitted by three participants in
2013 and 2014 only. The LC-MS/MS methods used by these par-
ticipants were based on HILIC-MS/MS with one participant (Lab
28) using the method of Boundy et al. [45].
5. Others: alternative methods for PSP determination include cap-
illary electrophoresis coupled to ultraviolet (UV) or MS detection,
although very little research has been carried out in this area
[47–52] and no QUASIMEME participants have submitted data
based on these technologies to date.
1.3. QUASIMEME’s Coﬁno model for data assessment
The data assessment carried out by QUASIMEME is based on ISO
guide 13528 concerning the proﬁciency testing of analytical chem-
istry laboratories [53] with some slight modiﬁcations. The assigned
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Fig. 2. Chromatograms of Tissue B (QST076BT, 095BT & 133BT) obtained by a) preCOX
LC-FLD analysis of carboxylic acid solid phase extraction (SPE) fraction 2, periodate
oxidised, b) preCOX LC-FLD analysis of C18 SPE cleaned, peroxide oxidised, c) PCOX
LC-FLD analysis of GTX/STX toxins and d) PCOX LC-FLD analysis of C-toxins.
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value and z-scores are calculated using a model developed by Coﬁno
et al. [54]whichwas speciﬁcally designed for use in the determination
of population characteristics [55]. Robust statistics form the basis to
the ISO13528 guide to data assessment but this model can be limited
where a high percentage of extreme values are submitted by par-
ticipants, as the model can typically deal with ~7–10% tailing data.
The Coﬁno model is unique as it can be used directly with a whole
range of datasets including tailing or skewed data, datasets contain-
ing extreme outliers and bimodal or multimodal distributions.
The model works by identifying clusters of data within a dataset
exhibiting a high level of agreement. From this the mean, stan-
dard deviation (s.d.) and percentage of data associated with each
cluster is calculated. A distinct advantage this model has over the
standard robust model is that no preparation of the dataset is nec-
essary, either by using subjective boundaries or outlier testing before
entering it into the database for assessment.
The Coﬁnomodel uses probability density functions for each ob-
servation weighting values centred around the mean more heavily
than those further away from the mean.
The detailed, graphical information provided by the model can
be seen in Fig. 3 and the derivation of each is described in the
QUASIMEME handbook [55]. The graphical information includes:
- A plot of the population density functions (Fig. 3a).
- Matrix overlap (Kilt) plot which is a colour density plot very sen-
sitive to identifying the structure of data, especially modality
(Fig. 3b).
- A ranked overview of the means and standard deviations of each
data set (Fig. 3c).
- Z-score plot for reviewing performance against targets (Fig. 3d).
1.4. Proﬁciency testing for PSP toxins
QUASIMEME currently provide the only commercially avail-
able, open access PT schemes for marine biotoxins in shellﬁsh
worldwide. Previous interlaboratory and PT schemes for PSP toxins
have focused on the MBA [56], on the preCOX LC-FLD method [57]
or on a combination of the most widely used methods including
MBA, preCOX and PCOX LC-FLD, ELISA and LC-MS/MS [58–62].
A pilot study organised by the Food Analysis Performance As-
sessment Scheme FAPAS® in 2003 highlighted issues related to the
choice of extraction method used by participants [63]. Under boiling
HCl conditions, partial hydrolysis of the N-sulfocarbamoyl toxins,
GTX5 and C1,2, present in the sample, were transformed into their
Fig. 3. Data plots for the toxin dcSTX found in sample QST132BT in 2012. a) Summed probability density functions (PDFs) for all data (black line) and for the ﬁrst mode,
PMF1, (blue line) with histogram of individual measurements in grey. Each observation from a participant is described by a PDF and is not regarded as a value using the
Coﬁno model. b) The Kilt plot (Overlap matrix) showing degree of overlap of each pair of data. Areas of the map coloured white indicate complete overlap (agreement) for
the observations concerned while black indicates no overlap. c) Ranked overview of all data with error bars of ±2 s.d. d) Ranked z-score plot for all data.
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carbamoyl counterparts, STX and GTX-2,3 respectively [36], leading
to signiﬁcant differences in the results supplied by users of both ex-
traction methods.
A ring trial organised by CEFAS in 2011/2012 found statistical
differences between the preCOX and PCOX methods, most notably
for the toxins GTX1,4 and NEO, with signiﬁcantly higher results on
average submitted by preCOX LC-FLD users compared to PCOX LC-
FLD. Conversely results returned for the other toxins covered in that
study, C1,2, GTX2,3 and STXwere found to be lower on average when
determined by preCOX LC-FLD compared to PCOX LC-FLD. The
organisers surmised that the higher levels of inter-laboratorymethod
variability associated with preCOX LC-FLD analysis, as evidenced by
the higher standard deviations submitted by participants contrib-
uted to the differences observed [59].
Other studies have highlighted issues relating to the analysis of
the toxins dcNEO and GTX6 by both LC-FLD methods. The toxin
dcNEO co-elutes with another toxin, NEO, when analysed using the
PCOXmethod, leading to potentially signiﬁcant over-estimations of
total toxicity due to the differences in TEF values for both toxins,
(Fig. 1). The lack of certiﬁed reference materials for all the known
PSP toxins but in particular GTX6 and C3,4, highlights another issue
between both LC-FLDmethods. An hydrolysis step, converting GTX6
into NEO and C3,4 into GTX1,4, can be applied by users of the preCOX
method, allowing indirect quantitation of these toxins, which is not
possible when using the PCOX method.
2. Materials and methods
All materials were prepared by the lead author and designed to
test the performance of QUASIMEME participant methods with the
analysis of a wide variety of analytes, whilst minimising the number
of samples to be tested. Materials incorporated a range of toxin con-
centrations and different complexities in toxin proﬁle composition.
The shellﬁsh tissues used were naturally contaminated with a range
of PSP toxins and prepared following in-house procedures to ensure
homogeneity. Stabilisation of the toxins and matrices was achieved
using a combination of heat treatment and the addition of antibi-
otics and an antioxidant [64,65] with short-term stability and
homogeneity studies performed on all materials before distribu-
tion to participants [66].
A total of eight materials have been used over the six exercises
2009–2014, with Tissues A & C being incorporated into four rounds
each, Tissues B & D used in three rounds, Tissue E used in two rounds
and Tissues F, G & H used in one round only. Table 2 lists each of
the materials and the rounds in which they were used, the as-
signed codes, predominant toxins present, matrices studied and the
homogeneity results determined. The coeﬃcients of variation were
calculated from the homogeneity data contained in Table 2 and com-
pared to expected levels of method variability determined through
validation of the test method, belowwhich the RMwas deemed suf-
ﬁciently homogenous.
The exercises are true proﬁciency tests so no standardisedmethod
protocol was provided by QUASIMEME and participants were re-
quested to use the analytical method routinely employed at their
laboratories. The only stipulation in the protocol was in the use of
TEFs supplied and these were requested to be used in total toxic-
ity calculations. In 2009 (Round (R) 57) and 2010 (R61), the TEFs
supplied in the protocol were those reported by Oshima [19], while
in 2011 (R65), 2012 (R69), 2013 (R72) and 2014 (R 2014-1) TEFs
recommended by the EFSA [20] were prescribed in the protocol
(Fig. 1).
The format of the data submitted by participants is dependent
upon the method employed for material testing. All participants are
required to submit a total toxicity result for each sample, enabling
assessment and comparison of all methodologies including par-
ticipants using MBA. Participants using either the preCOX, PCOX or
LC-MS/MS methods of analysis, where individual analogue con-
centrations can be determined, were able to submit results such that
a data assessment and therefore z-scores can be calculated for each
individual toxin, or epimeric pair, in addition to total toxicity. This
allows participants receiving less than satisfactory z-scores to pin-
point potential causes of method failure or operator error, if they
relate to the determination of a particular analogue.
3. Intercomparison results
Table 3 summarises participants’ data taken over the six exer-
cises and contains assigned values, number of observations per
determinant, between-laboratory CV (%) and percentage of partici-
pants receiving satisfactory z-scores. The performance of laboratories
was not assessed in cases where an assigned value could not be cal-
culated. In these cases an indicative value was generated and no
z-scores were calculated. Onlymaterials where assigned values could
be calculated are listed in table 3. The criteria set out in calculat-
ing an assigned value and z-scores are contained in the QUASIMEME
manual [55].
Table 2
List of materials used in each exercise, assigned codes, predominant toxins present, matrices studied and homogeneity results determined using OMA AOAC2005.06
Tissue Rounds Used Year Codes Used Predominant Toxins Present Matrix Homogeneity Results (n = 15)
μgSTXdiHCl eq./kg
A 57 2009 QST075BT dcSTX, STX, GTX-5 Mytilus galloprovincialis 533 ± 24
61 2010 QST093BT
69 2012 QST132BT
2014-1 2014 Sample 1
B 57 2009 QST076BT dcSTX, GTX-2,3, GTX-1,4, STX,
GTX-5 & C-1,2
Mytilus edulis & Mytilus
galloprovincialis
1174 ± 45
61 2010 QST095BT
69 2012 QST133BT
C 61 2010 QST094BT dcGTX-2,3, dcSTX & dcNEO Spisula solida 2829 ± 62
65 2011 QST111BT
69 2012 QST134BT
2014-1 2014 Sample 2
D 65 2011 QST113BT GTX-2,3 & STX Mytilus edulis 1400 ± 44
72 2013 QST152BT
2014-1 2014 Sample 3
E 65 2011 QST114BT GTX-2,3, STX & dcSTX Mytilus edulis 1249 ± 55
72 2013 QST154BT
F 69 2012 QST135BT GTX-2,3, STX, GTX-1,4 & NEO Crassostrea gigas 803 ± 22
G 72 2013 QST155BT GTX-2,3, STX, GTX-1,4 & dcSTX Mytilus edulis 829 ± 29
H 2014-1 2014 Sample 4 GTX-2,3, STX, GTX-1,4 & dcSTX Crassostrea gigas 1715 ± 51
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Table 3
Summary data from all methods 2009–2014, showing assigned values, number of observations, coeﬃcient of variation and % of z-scores satisfactory
Year Test Material and Code STX dcSTX dcGTX-2 dcGTX-3 dcGTX-2,3 C-1,2 GTX-2 GTX-3 GTX-2,3 GTX-5 GTX-1 GTX-4 GTX-1,4 neoSTX dcNEO Total Toxicity
μmol/kg μgSTXdiHCleq./kg
2009 Mussel QST075BT Tissue A 461, 14
35, 50
Mussel QST076BT Tissue B 977, 14
44, 50
2010 Mussel QST093BT Tissue A 0.07, 6 1.69, 13 0.20, 10 400, 16
31, 42 34, 85 39, 69 44, 50
Clam QST094BT Tissue C 3.47,14 1.37, 7 1886, 16
41, 50 36, 57 45, 44
Mussel QST095BT Tissue B 0.37, 11 0.93, 13 0.48, 8 1.36, 11 0.13, 7 1.14, 8 0.17, 5 950, 15
23, 77 28, 71 43, 50 13, 75 16, 46 22, 55 58, 33 36, 44
2011 Clam QST111BT Tissue C 3.53, 12 9.32, 7 1.40, 8 2670, 19
14, 83 29, 71 20, 63 19, 89
Mussel QST113BT Tissue D 2.56, 12 1.01, 5 1.15, 7 1139, 19
15, 83 22, 80 29, 86 30, 58
Mussel QST114BT Tissue E 1.92, 12 0.58, 12 1.54, 7 1187, 19
16, 75 27, 92 18, 71 27, 63
2012 Mussel QST132BT Tissue A 0.08, 10 1.71, 13 0.21, 10 629, 15
63, 69 23, 69 20, 75 18, 60
Mussel QST133BT Tissue B 0.35, 14 0.97, 13 0.35, 6 1.09, 8 0.12, 7 0.83, 5 0.90, 7 0.14, 6 986, 15
23, 86 29, 69 26, 71 21, 75 4, 64 14, 80 19, 86 35, 56 32, 53
Clam QST134BT Tissue C 3.34, 13 9.00, 8 0.10, 4 1.32, 9 2734, 15
18, 62 24, 63 44, 44 24, 67 19, 67
Oyster QST135BT Tissue F 0.60, 14 1.62, 7 0.69, 7 0.12, 7 789, 15
28, 86 21, 71 39, 50 80, 50 38, 47
2013 Mussel QST152BT Tissue D 2.59, 19 1.06, 6 0.45, 6 1.31, 12 1245, 18
13, 68 5, 100 2, 100 27, 92 11, 72
Mussel QST154BT Tissue E 1.98, 19 0.56, 17 1.36, 6 0.54, 6 1.53, 12 1246, 18
20, 68 25, 76 17, 100 5, 83 18, 83 17, 78
Mussel QST155BT Tissue G 0.32, 18 0.54, 17 0.84, 6 0.30, 6 0.95, 12 0.17, 5 0.54, 10 742, 17
27, 78 26, 76 25, 100 7, 83 17, 83 48, 83 38, 64 19, 67
2014 Mussel Sample 1 Tissue A 0.10, 13 1.96, 21 0.20, 13 750, 22
77, 65 31, 57 45, 75 33, 55
Clam Sample 2 Tissue C 3.46, 20 11.20, 6 3.07, 6 10.20, 14 1.46, 13 3045, 22
24, 65 4, 100 9, 67 37, 50 53, 46 22, 68
Mussel Sample 3 Tissue D 2.61, 20 0.94, 6 0.42, 6 1.21, 14 1289, 21
18, 80 9, 83 12, 100 32, 79 17, 71
Mussel Sample 4 Tissue H 1.94, 21 0.09, 13 2.24, 7 0.74, 7 2.41, 14 0.17, 6 0.74, 9 0.24, 11 1569, 22
9, 90 55, 63 8, 86 7, 100 25, 64 27, 86 45, 55 47, 57 15, 68
Codes: assigned value, number of observations (Nobs) / coeﬃcient of variation % (CV%), % z-scores satisfactory (|z| <2).
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Figs 4 and 5 graphically represent z-scores generated over the
last six exercises with calculated upper and lower z-score limits for
satisfactory (z ≤ |2|), questionable (|2| < z ≤ |3|) and unsatisfactory
(z ≥ |3|) data.
A list of the methods used by participants since 2009, includ-
ing references where possible, is detailed in Table 4. Please note that
labs 3 and 8 changed from using the MBA as their method of anal-
ysis in R57 (2009) to using preCOX and PCOXmethods respectively,
when they next participated in 2010 and 2011.
All materials were prepared from naturally contaminated tissues
at levels ranging from approximately half to three and a half times
the current EU regulatory limit of 800micrograms per kilogram [15].
The materials were chosen to test participant performance using
the most common shellﬁsh species of global commercial impor-
tance where possible, with toxin proﬁles of varying complexity and
over a range of concentrations. The results summarised in Table 3
show the improvement of participants over the six exercises. The
coeﬃcients of variation have decreased from an average of 39% in
2009 to 22% in 2014 and the percentage of participants receiving
satisfactory z-scores have increased from an average of 50% in 2009
to 65% in 2014.
Although substantial improvements have beenmade during these
development exercises certain issues have been highlighted which
may have contributed to some of the variability seen in the datasets.
The application of TEFs to estimate the total toxicity of a sample
was necessary in order to compare allmethods together. Two different
sets of TEFs have been prescribed in the protocols over the last 6 years
as described in the previous section. The differences between both
sets of TEFs are minimal apart from one toxin, dcSTX, which was in-
creased from 0.5 to 1.0 by the EFSA. These changes account for the
variability in assigned values of materials used in multiple rounds
where dcSTXwas a predominant toxin present. This is clearly evident
in tissues A and C where assigned total toxicity values of 461 and
400 μg STX diHCleq./kg (tissue A) and 1886 μg STX diHCleq./kg (tissue
C) in early rounds increased to 629 and 750 μg STX diHCleq./kg (tissue
A) and 2670, 2734 and 3045 μg STX diHCleq./kg (tissue C) in latter
exercises. Fig. 6 illustrates this point and graphically presents the as-
signed values for all tissues used in these exercises. Recent studies
carried out by Munday et al. determined the median lethal doses of
some PSP analogues through interperitoneal injection, gavage and
feeding experiments [67]. They concluded that there was a lower risk
with dcSTX than that proposed by the EFSA with their ﬁgures being
more in line with earlier data such as those determined by Oshima
et al. [19]. Thismay explain some of the differences observed between
instrument based methods of analysis and the MBA in samples with
dcSTX as a predominant toxin present.
Another interesting observation from the data contained in
Table 3 relates to the comparison of methods capable of epimer
separation, such as the PCOX and LC-MS/MSmethods to the preCOX
method, where epimer separation is not possible. In tissues where
values were assigned to both individual epimers as well as the sum
of the epimers, signiﬁcant differences can be observed. In the
2009 2012
PCOX ELISA
2013
LC-MS/MS
2010
MBA
2011 2014
preCOX
z-score +/- 3
z-score +/- 2
Did not participate / submit
Tissue A
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
z-score
-6
-4
-2
0
2
4
6
Tissue B
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
-6
-4
-2
0
2
4
6
Tissue C
Laboratory Number
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
-6
-4
-2
0
2
4
6
Fig. 4. Distribution of participants’ z-scores for Tissues A–C used in various rounds from 2009–2014.
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determination of GTX2 and GTX3, present in all three tissues used
in 2013, the addition of both assigned values for each individual
epimer, determined by PCOX LC-FLD and LC-MS/MS users only, was
substantially higher than the assigned value of the epimers deter-
mined together by preCOX LC-FLD users only. This was also observed
in tissues D and H used in 2014 for GTX 2 and GTX3 but also for
the toxins dcGTX2 and dcGTX3 in tissue C in 2014. This observa-
tion is surprising given the accepted overestimation of epimer
concentrations determined when using the preCOX LC-FLD method
as the more toxic analogue of each epimer pair is used to calcu-
late total toxicity. As in the case of the CEFAS ring trial discussed
previously, the higher inter-laboratory method variability of the
preCOX LC-FLD method may explain some of the differences
observed.
Where individual analogues could be determined by a method
such as preCOX and PCOX LC-FLD and LC-MS/MS, assigned values
could be calculated from the datasets if certain conditions, as high-
lighted in the Quasimeme handbook were met [55]. The analysis
of one analogue, NEO has been problematic for participants as evi-
denced by the high %CVs, with an average value of 55% (n = 4)
calculated from the four datasets where assigned values could be
determined for this toxin (Table 3). This value is high when com-
pared to other individual analogues determined in QUASIMEME
tissues with average %CVs determined for dcNEO (33%, n = 4) and
GTX5, dcSTX and STX (28% each, n = 13). This observation is not sur-
prising given the fact that NEO co-elutes with dcSTX, if also present
in a sample, when determined by the preCOX LC-FLD method. In
this instance the NEO concentration in a sample is estimated through
a back calculation which takes into account the dcSTX contribu-
tion to the overall response. PCOX LC-FLD and LC-MS/MS methods
can directly determine this toxin so no back calculation is required.
4. Discussion
4.1. Identiﬁcation of poor performance
The source or sources of poor performance in PT schemes can
be diﬃcult to pinpoint for both the participant and organiser. Finding
correlations between method choice and analytical performance is
very diﬃcult even with the large amount of data submitted by par-
ticipants over the last six years. This is mainly due to the large
number of variabilities potentially inﬂuencing PSP analysis and
results, for example changes to staff and associated training, re-
agents used, slight variations in the oxidation of toxins or batch to
batch variability of consumables such as SPE cartridges.
The majority of extreme z-scores (z ≥ |6|) received by partici-
pants can be traced back to either gross calculation errors (as high
as 2–3 orders of magnitude difference) made during the conver-
sion of concentration data into total sample toxicities or the
misidentiﬁcation of toxins present. Adequate training of person-
nel, particularly new employees, in-house validation of methods and
a comprehensive review process prior to submission is therefore
Fig. 5. Distribution of participants’ z-scores for Tissues D–F used in various rounds from 2011–2014.
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of huge importance and wouldminimise or eliminate these extreme
results. Experienced laboratories can also suffer from variable per-
formance levels due to the recruitment of new staff requiring training
or the implementation of newmethodologies and instrumentation.
While the causes of extreme z-scores are in general easier for
participants to trace and remedy, unsatisfactory z-scores (|3| < z < |6|)
can be a lot more diﬃcult to investigate. New participants to these
schemes typically take two to three exercises before receiving sat-
isfactory z-scores, the exact causes of which are unknown but are
most likely because of their unfamiliarity with the submission
process, reporting units required or analysing toxin proﬁles atyp-
ical of their geographical location. This can be seen in Fig. 4,
particularly for laboratories 1, 2 and 4 where initial unsatisfactory
z-scores received in the ﬁrst round were improved in subsequent
exercises. The opposite of this can also be the case however (see
laboratory 5 in Fig. 4) so participants have to be continually vigi-
lant to ensure satisfactory performances are maintained.
4.2. Factors affecting poor performance
Previous PT schemes, ring trials and interlaboratory studies for
PSP toxins have highlighted issues related to each of the methods
used [56,57,59,63]. The MBA is known to suffer from recovery issues
caused by “salt” effects [56] and the presence of some metals, par-
ticularly zinc can have a large suppressive effect on the bioassay [24]
with underestimation of total toxicity particularly in samples close
to the EU regulatory limit. These observations could explain some
of the MBA results returned by participants in particular tissues B-E
where results were consistently below the assigned value (24 of 27
in total) with some results ~60% below the assigned value.
The choice of extraction method can also have a fundamental
inﬂuence on results, with previous studies showing that under
boiling HCl conditions (MBA & PCOX methods), partial hydrolysis
of the N-sulfocarbamoyl toxins, GTX-5 and C-1,2 transformed them
into their carbamoyl counterparts, STX and GTX-2,3 respectively [63].
It was noted however that the N-sulfocarbamoyl toxins were not
present at very high concentrations in the tissues used in these
exercises.
4.3. CRMs
The lack of certiﬁed reference materials (CRMs), both solvent and
matrix for all the PSP toxins is a problem consistently highlighted
in the area, although a matrix CRM has recently been produced by
CEFAS [68]. This lack of CRMs, particularly for the toxins GTX6 and
C3,4, although not present in any QUASIMEME samples to date, has
highlighted problems in the PT schemes delivered by the EU Ref-
erence Laboratory for Marine Biotoxins (EURL-MB) [60,61].
Participants using preCOX methods can perform an hydrolysis step
converting GTX6 into NEO and C3,4 into GTX1,4 which allows an
indirect means of quantiﬁcation for those toxins. Although the tox-
icity of GTX6 is relatively low it can still contribute signiﬁcantly to
the overall toxicity of some samples [35].
4.4. Misidentiﬁcation of toxins
The misidentiﬁcation of toxins, particularly dcNEO has been an
issue for some participants and has been a source of poor perfor-
mance in these exercises. The dcNEO misidentiﬁcation was
particularly highlighted in the analysis of Tissue C. Users of PCOX
methods of analysis misidentify this toxin as NEO due to themethods
inability to separate both toxins unless a very long run time is utilised
(>60 mins). This is an accepted limitation of the PCOX method and
presents no consumer risk in a real sample scenario owing to the
10-fold difference in TEF values between the two toxins. It can lead
to a signiﬁcant over estimation of total toxicity owing to the dif-
ferences in TEF however, and for the most part resulted in
participants receiving unsatisfactory or extreme z-scores. This was
not always the case however as some laboratories received satis-
factory z-scores even with dcNEO misidentiﬁed, (see laboratories
8 and 15 in 2011, 2012 and 2014 for Tissue C, Fig. 4). The analysis
of dcNEO can also pose problems to preCOX participants as this toxin
co-elutes with dcSTX, and requires a back calculation in order to
estimate the dcNEO concentration in the sample. Only two preCOX
participants (Lab 11 & 14) have failed to correctly identify dcNEO
as being present in Tissue C in 2010. Lab 11 received an unsatis-
factory z-score for this sample while Lab 14 received a satisfactory
z-score as they signiﬁcantly overestimated the dcSTX content in the
sample, negating the fact that dcNEO was not quantiﬁed and used
in the total toxicity calculation. In subsequent rounds Lab 11 cor-
rectly identiﬁed dcNEO in this sample and received satisfactory
z-scores again highlighting participant improvements as experi-
ence is gained. Lab 14 did not participate in subsequent rounds. As
no data is removed by QUASIMEME before assigned values and
z-scores are calculated, the onus is on participants to have a com-
prehensive review process of ﬁnal reports and z-score results to
ensure correct identiﬁcation of all toxins present in the materials
has been achieved. Personalised feedback to participants, particu-
larly those with less than satisfactory performance is not provided
Table 4
Overview of methods used from 2009–2014 with references where applicable
Lab Number Method Used
2009 2010 2011 2012 2013 2014
1 1 1 1 1 1 1
2 1 1 1 1 1 1
3 2 – 1 1 1 1
4 2 2 2 2 2 2
5 3 3 3 – – 4
6 1 1 1 1 1 1
7 1 1 1 1 1 1
8 2 4 4 4 4 4
9 1 1 1 1 1 –
10 1 1 – 1 1 1
11 1 1 1 1 1 –
12 4 – – – – –
13 2 2 2 – – –
14 – 1 – – – –
15 4 4 4 4 4 4
16 – 4 – – 4 4
17 – 1 1 1 1 1
18 – 4 4 4 – –
19 – – 4 4 4 4
20 – – – 4 – –
21 – – 5 – – –
22 – – 2 2 – –
23 – – 2 – – –
24 – – 5 – – –
25 – – – – 4 –
26 – – – – 1 1
27 – – – – 6 6
28 – – – – – 6
29 – – – – – 1
30 – – – – – 6
31 – – – – – 1
32 – – – – – 7
33 – – – – – 1
34 – – – – – 1
35 – – – – – 2
Codes: 1. OMA AOAC 2005.06 [28]
2. OMA AOAC 959.08 [22]
3. Oshima (PCOX) [19]
4. OMA AOAC 2011.02 [34]
5. ELISA (Ridascreen)
6. HILIC-MS-MS
Internal method
7. DIN EN 14526 [26]
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by QUASIMEME after each round due to the extensive scope of their
program, the number of determinants in each exercise coupled with
the logistical problems this approach would entail. The relevant au-
thorities in each participant’s country, such as national accreditation
bodies should comprehensively review PT results to ensure that the
accurate identiﬁcation of toxins present has been adequately
demonstrated.
4.5. Method recovery correction factors
The application of method recovery correction factors to results
generated from preCOX analysis is an important issue and has been
high on the agenda of the EURL-MB Working Group for PSP toxins
over the last number of years. Only one QUASIMEME participant
has submitted both non-recovery corrected (lab 10) and recovery
corrected (Lab 26) results in 2013 and 2014 (Figs 4 and 5), with none
of the recovery corrected results receiving satisfactory z-scores in
either round. This observation is not surprising given the fact that
the assigned values (from which z-scores are calculated) gener-
ated for each tissue are calculated from the group which is weighted
more heavily by non-recovery correcting participants. In order to
assess all data together the application of recovery correction factors
would need to be stipulated in future protocols.
4.6. Method dependency and individual analogues
Finding correlations between proﬁciency test performance and
method choice or between performance and the presence of spe-
ciﬁc analogues in test samples is diﬃcult. For instance the plot of
the population density functions in Fig. 3a clearly shows a bi-
modal distribution of the data in the determination of dcSTX in
sample QST132BT with the smaller mode (PMF2) resulting from
PCOX users (3 labs). The main mode of data (PMF1) was shown to
arise from the remaining preCOX users, although one PCOX partic-
ipant is also contained in this main mode of data. Another sample,
QST133BT used in the same round also showed a bimodal distri-
bution in the determination of dcSTX (data not shown). It might be
easy to deduce from this and the Kilt plot (Fig. 3b) that there is a
method dependency issue between both LC-FLD methods relating
to the analysis of dcSTX. This trend however, is not consistent, as
the analysis of the same two samples in 2009 and 2010 showed no
bi-modality for this toxin with the entire data set ﬁtting a Gauss-
ian distribution and results from PCOX users randomly spread
throughout the entire series. Furthermore other samples used in
these exercises that contained dcSTX showed no bi-modality in their
distributions.
ELISA results showed variable performance levels with the only
analysis of Tissue C (lab 24, Fig. 4) by this method producing a sat-
isfactory z-score, whereas ELISA analysis carried out on Tissues D
and E (lab 21 and 24, Fig. 5) produced all extreme z-scores (>6).
Tissues D and E contain the toxins GTX2,3 and STX, with Tissue E
also containing dcSTX. This proﬁle is relatively simple and would
represent a fairly standard North European proﬁle so the ELISA results
if not pertaining to analyst or submission errors should be further
investigated.
Although LC-MS/MS has not been used extensively in PSP PT
schemes to date, results generated by this method are encourag-
ing with only one unsatisfactory result submitted to date with most
receiving satisfactory z-scores. LC-MS/MS participants have also dem-
onstrated the applicability of their methods to cover a variety of
different toxin proﬁles with satisfactory results received from a range
of different samples [46].
Although we have attempted to look for correlations between
method choice and performance, no obvious or consistent pat-
terns could be discerned however.
4.7. Method choice
Choosingwhichmethod to use in determining PSP toxins depends
on the ﬁnal requirements of the laboratory with eachmethod having
Fig. 6. Assigned values determined in multiple rounds for Tissues A–E and in single rounds for Tissues F–H.
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its own advantages and limitations [24,35]. In a routine monitor-
ing scenario laboratories in the EU or exporting into the EU are legally
bound to use designated methods of analysis such as the MBA or
OMA AOAC 2005.06. The MBA is still the reference method in the
EU however. Each of the methods used over the previous six exer-
cises have demonstrated their applicability for these purposes but
have also highlighted the potential pitfalls, with each method re-
ceiving the entire range of possible z-scores, satisfactory,
questionable, unsatisfactory and extreme. No one method stands
out as providing a clear advantage over the others so the ﬁnal choice
may be based on practical issues associated with the method, access
and cost of equipment or the training and skills of the analyst, rather
than any perceived shortcomings of each method.
MS determination of PSP toxins is desirable primarily based on
the speciﬁcity the method provides and the signiﬁcant reduction
of matrix related problems recently reported have eliminated crit-
ical issues affecting method performance.
The LC-MS/MS results highlight the applicability of using HILIC-
MS/MS technology for the separation and determination of PSP toxins
with only one of thirteen results submitted to date receiving an un-
satisfactory z-score.With sensitivity issues greatly improved through
the application of an SPE clean-up step, detection limits are com-
parable or below those of the more established AOAC oﬃcial
methods. Each of the oﬃcial AOAC methods based on LC-FLD have
suﬃcient sensitivity to enable effective monitoring at current reg-
ulatory levels however.
Sample turnaround times using the method of Boundy et al. [45]
are increased through the application of an SPE clean-up step com-
pared to the original HILICmethod of Dell’Aversano et al. [44]. Sample
turnaround times are however similar when compared to both AOAC
LC-FLD methods where two SPE steps and two oxidation reac-
tions may need to be performed on a single sample (AOAC2005.06),
or two chromatographic runs in the case of AOAC 2011.02. SPE can
be fully automated and the application of UPLC technology greatly
reduces analysis times which are critical in its application to a high
throughput statutory monitoring scenario.
4.8. Performance improvements
Overall the development of this exercise and the performance
of participating laboratories have improved since its inception in
2009. Participant numbers have increased which highlights the
strengthening of the exercise and its economic sustainability going
forward. The performance of laboratories has mostly improved and
this is clearly evidenced from Fig. 7 which displays the averages of
both the coeﬃcient of variation for all samples in each round and
the percentage of participants receiving satisfactory z-scores. The
percentage of participants receiving satisfactory z-scores has in-
creasedmost years as laboratories gain experience in these exercises
and in determining potentially atypical toxin proﬁles. The preci-
sion of the laboratories as expressed by the coeﬃcient of variation
has also showed signs of signiﬁcant improvement from the early
exercises in 2009 and 2010.
The datasets also compare favourably with the PSP PT scheme
operated by the EURL-MB and the lipophilic biotoxin exercise (BT-
11) operated by QUASIMEME. In 2012 and 2013 where data from
all methods was assessed together by the EURL-MB, between lab-
oratory %CVs ranged from 33–52% in 2012 and 25–44% in 2013. In
2014 the EURL-MB did not assess the entire dataset from all par-
ticipants together so comparison to the 2014 QUASIMEME PSP data
was not possible. The QUASIMEME lipophilic biotoxin exercise in
2014 generated between laboratory %CVs in the range 20–38%, which
equated to between 45–80% of participants receiving satisfactory
z-scores. These exercises compare favourably with the QUASIMEME
PSP exercise over the same period with average %CVs of 27, 15 and
22% in the years 2012–2014 equating to 56, 72 and 66% of partici-
pants receiving satisfactory z-scores respectively.
Through adding PSP toxins to their scope, QUASIMEME have es-
tablished a comprehensive PT scheme for all EU regulated shellﬁsh
biotoxins.
5. Conclusions
Six development exercises for PSP toxins have been delivered
since 2009 by QUASIMEME, with participation from laboratories in
the EU, the Americas, Asia and Oceania using a range of different
methods of analysis based on LC-FLD, LC-MS/MS, animal toxicity
and immuno-based assays.Whilst no speciﬁc and consistent method
dependency issues could be detected from the datasets, factors af-
fecting poor performance were highlighted with suggestions made
on how improvements could be made by participants. Monitoring
the trends in z-scores from consecutive rounds has allowed
QUASIMEME to determine which participants have improved, de-
clined or maintained performance in these exercises.
The range of different methods used by QUASIMEME partici-
pants has highlighted the choice available for determining PSP toxins
in shellﬁsh. All the methods used over the previous six exercises
have received the full range of z-scores from satisfactory to extreme.
The choice of which method to use is therefore dependent on leg-
islative requirements in the participants region, access and cost of
equipment and the training and skills of the analyst rather than any
perceived limitations of a particular method.
The use of HILIC-MS/MS technology in determining PSP toxins
has shown the comparability this technique has compared to the
other more establishedmethods in routine monitoring programmes
worldwide. Recent advances that have overcome issues affecting
method performance have, for the ﬁrst time provided a viable MS
alternative for routine monitoring purposes. It is recommended that
this modiﬁed HILIC-MS/MSmethod should be considered for further
validation through a full collaborative study under the auspices of
the AOAC or other relevant bodies.
QUASIMEMEwill continue to deliver a PSP exercise annually with
data continually monitored by the Scientiﬁc Advisory Board (SAB)
to determine issues contributing to poor performance and any
method related issues.
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